Tapering biologic and conventional DMARD therapy in rheumatoid arthritis: current evidence and future directions

Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis

(2015) Ronald F van Vollenhoven et al.   ANNALS OF THE RHEUMATIC DISEASES

Relapse rates in patients with rheumatoid arthritis in stable remission tapering or stopping antirheumatic therapy: interim results from the prospective randomised controlled RETRO study

(2015) Judith Haschka et al.   ANNALS OF THE RHEUMATIC DISEASES

Step-down strategy of spacing TNF-blocker injections for established rheumatoid arthritis in remission: results of the multicentre non-inferiority randomised open-label controlled trial(STRASS: Spacing of TNF-blocker injections in Rheumatoid ArthritiS Study)

(2015) Bruno Fautrel et al.   ANNALS OF THE RHEUMATIC DISEASES

Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force

(2015) Josef S Smolen et al.   ANNALS OF THE RHEUMATIC DISEASES

Incidence and Predictors of Biological Antirheumatic Drug Discontinuation Attempts among Patients with Rheumatoid Arthritis in Remission: A CORRONA and NinJa Collaborative Cohort Study

(2015) K. Yoshida et al.   JOURNAL OF RHEUMATOLOGY

Predictive value of Doppler ultrasound-detected synovitis in relation to failed tapering of biologic therapy in patients with rheumatoid arthritis

(2015) Esperanza Naredo et al.   RHEUMATOLOGY

Klinische Remission bei rheumatoider Arthritis

(2015) K. Albrecht et al.   ZEITSCHRIFT FUR RHEUMATOLOGIE

Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non-inferiority trial

(2015) N. van Herwaarden et al.   BMJ-British Medical Journal

Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non-inferiority trial

(2015) N. van Herwaarden et al.   BMJ-British Medical Journal

THU0152 The Poet-Us Study: Can Ultrasonography Predict Flare in Patients with RA and Persistent Low Disease Activity in Whom the Tnfinhibitor (TNFI) is Stopped? Preliminary Results of an Ongoing Study

(2014) F. B. G. Lamers-Karnebeek et al.   ANNALS OF THE RHEUMATIC DISEASES

A randomised controlled trial of etanercept and methotrexate to induce remission in early inflammatory arthritis: the EMPIRE trial

(2014) J L Nam et al.   ANNALS OF THE RHEUMATIC DISEASES

Clinical and radiographic outcomes at 2 years and the effect of tocilizumab discontinuation following sustained remission in the second and third year of the ACT-RAY study

(2014) T W J Huizinga et al.   ANNALS OF THE RHEUMATIC DISEASES

Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period

(2014) Paul Emery et al.   ANNALS OF THE RHEUMATIC DISEASES

Discontinuation of tumour necrosis factor inhibitors in patients with rheumatoid arthritis in low-disease activity: persistent benefits. Data from the Corrona registry

(2014) Arthur Kavanaugh et al.   ANNALS OF THE RHEUMATIC DISEASES

Intensive Intervention Can Lead to a Treatment Holiday from Biological DMARDs in Patients with Rheumatoid Arthritis

(2014) Yoshiya Tanaka et al.   DRUGS

Sustained Remission with Etanercept Tapering in Early Rheumatoid Arthritis

(2014) Paul Emery et al.   NEW ENGLAND JOURNAL OF MEDICINE

Prediction of Relapse After Discontinuation of Biologic Agents by Ultrasonographic Assessment in Patients With Rheumatoid Arthritis in Clinical Remission: High Predictive Values of Total Gray-Scale and Power Doppler Scores That Represent Residual Synovial

(2014) Taro Iwamoto et al.   ARTHRITIS CARE & RESEARCH

Time trends in disease activity, response and remission rates in rheumatoid arthritis during the past decade: results from the NOR-DMARD study 2000–2010

(2013) Anna-Birgitte Aga et al.   ANNALS OF THE RHEUMATIC DISEASES

Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study

(2013) Yoshiya Tanaka et al.   ANNALS OF THE RHEUMATIC DISEASES

Remission induction comparing infliximab and high-dose intravenous steroid, followed by treat-to-target: a double-blind, randomised, controlled trial in new-onset, treatment-naive, rheumatoid arthritis (the IDEA study)

(2013) J L Nam et al.   ANNALS OF THE RHEUMATIC DISEASES

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update

(2013) Josef S Smolen et al.   ANNALS OF THE RHEUMATIC DISEASES

Sustained Clinical Remission and Rate of Relapse After Tocilizumab Withdrawal in Patients with Rheumatoid Arthritis

(2013) L. Aguilar-Lozano et al.   JOURNAL OF RHEUMATOLOGY

Five-year Favorable Outcome of Patients with Early Rheumatoid Arthritis in the 2000s: Data from the ESPOIR Cohort

(2013) B. Combe et al.   JOURNAL OF RHEUMATOLOGY

Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial

(2013) Josef S Smolen et al.   LANCET

Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial

(2013) Josef S Smolen et al.   LANCET

Drug free REmission/low disease activity after cessation of tocilizumab (Actemra) Monotherapy (DREAM) study

(2013) Norihiro Nishimoto et al.   Modern Rheumatology

Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naïve patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study

(2012) Jacqueline Detert et al.   ANNALS OF THE RHEUMATIC DISEASES

Down-titration and discontinuation of infliximab in rheumatoid arthritis patients with stable low disease activity and stable treatment: an observational cohort study

(2012) Aatke van der Maas et al.   ANNALS OF THE RHEUMATIC DISEASES

Discontinuation of infliximab and potential predictors of persistent low disease activity in patients with early rheumatoid arthritis and disease activity score-steered therapy: subanalysis of the BeSt study

(2011) M. van den Broek et al.   ANNALS OF THE RHEUMATIC DISEASES

American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials

(2011) David T. Felson et al.   ARTHRITIS AND RHEUMATISM

Drug-free remission: is it already possible?

(2011) Marianne van den Broek et al.   CURRENT OPINION IN RHEUMATOLOGY

When to initiate and discontinue biologic treatments for rheumatoid arthritis?

(2011) K. Chatzidionysiou et al.   JOURNAL OF INTERNAL MEDICINE

The Pathogenesis of Rheumatoid Arthritis

(2011) Iain B. McInnes et al.   NEW ENGLAND JOURNAL OF MEDICINE

'I'm hurting, I want to kill myself': rheumatoid arthritis flare is more than a high joint count--an international patient perspective on flare where medical help is sought

(2011) S. Hewlett et al.   RHEUMATOLOGY

Discontinuing treatment in patients with rheumatoid arthritis in sustained clinical remission: exploratory analyses from the BeSt study

(2010) N. B. Klarenbeek et al.   ANNALS OF THE RHEUMATIC DISEASES

Patients with RA in remission on TNF blockers: when and in whom can TNF blocker therapy be stopped?

(2010) B. Saleem et al.   ANNALS OF THE RHEUMATIC DISEASES

Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study

(2010) Y. Tanaka et al.   ANNALS OF THE RHEUMATIC DISEASES

Weekly home self-assessment of RAPID-4/3 scores in rheumatoid arthritis: A 6-month study in 26 patients

(2010) Anne Blanchais et al.   JOINT BONE SPINE

Benefits 8 years after a remission induction regime with an infliximab and methotrexate combination in early rheumatoid arthritis

(2010) V. Bejarano et al.   RHEUMATOLOGY

Withdrawal of disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a systematic review and meta-analysis

(2009) R. O'Mahony et al.   ANNALS OF THE RHEUMATIC DISEASES

Prevalence of and predictive factors for sustained disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: Results from two large early arthritis cohorts

(2009) Diane van der Woude et al.   ARTHRITIS AND RHEUMATISM

Effect of discontinuing TNFα antagonist therapy in patients with remission of rheumatoid arthritis

(2009) Olivier Brocq et al.   JOINT BONE SPINE

Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial

(2009) RF van Vollenhoven et al.   LANCET

Evaluation of two strategies (initial methotrexate monotherapy vs its combination with adalimumab) in management of early active rheumatoid arthritis: data from the GUEPARD trial

(2009) M. Soubrier et al.   RHEUMATOLOGY